CEACAM1 ANTIBODIES FOR ANTI-VIRAL THERAPY
Ref-No: TA-4782

BACKGROUND

Cytotoxic CD8-positive T cells constitute the crucial leukocyte subpopulation for a cellular response against viral infection. Since only very few direct anti-viral therapeutics are available, the stimulation of an efficient and specific immune response against a viral infection is a valid alternative or additional therapeutic approach. The first of such strategies has been established by use of high doses of interferon, which however has a high risk of adverse reactions of the immune system, and low response rates. Therefore, it is mandatory to search for further immune stimulatory strategies that more specifically induce an anti-viral T cell response. The herein described approach is based on an antibody-mediated stimulation of the carcino-embryonic antigen-related cell adhesion molecule 1 (CEACAM1), which activates early parts of both the B cell and T cell receptor-induced signal transduction.

SOLUTION

The researchers have shown on the example of the lymphocytic choriomeningitis virus (LCMV) that these antibodies stimulate the activation and expansion of virus specific cytotoxic T cells, which comes along with a reduced virus load in serum and organs of mice. In vitro studies confirmed efficacy also against influenza virus and cytomegalovirus.

The researcher have conducted experiments with a LMCV-specific immune response mouse model. Further proof of principle with the humanized variant of the antibody has been provided by means of humanized CEACAM1 mice. The antibody activates human virus-specific CD8+ T cells in vitro.

ADVANTAGES

- Complementary anti-viral therapy option
- Applies to a broad range of viruses
- Specific immune response against specific viruses

SERVICE

PROvendis GmbH
Dipl.-Biol. Kordula Kruber
+49.208 94105-30
kk@provendis.info
www.provendis.info

DEVELOPMENT STATUS

Pre clinical

CATEGORIES

//Life Sciences //White biotechnology //Antibodies, hybridoma //Medicine and pharmaceutics //Therapy and therapeutics

www.inventionstore.de
The monoclonal, humanized anti-CEACAM1 antibodies are offered for licensing and further therapeutic development. In case of interest we are pleased to inform you about the patent status.

PUBLICATIONS & LINKS
